SCHEMBL22014379

SCHEMBL22014379

C(=C/c1cnoc1)\c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
PDGFRB P09619 1/20 0.44
PDGFRA P16234 1/20 0.44
MAOB P27338 3/20 0.42
NFE2L2 Q16236 2/20 0.42
CYP19A1 P11511 2/20 0.42
MAOA P21397 2/20 0.42
RELA Q04206 1/20 0.42
GRM5 P41594 1/20 0.41
TTR P02766 1/20 0.39
ALOX5 P09917 1/20 0.39
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
GRM4 Q14833 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2459744 0.74 RAB9A (0.36) ALDH1A1
Benzene SCHEMBL27467957 0.73 ALDH1A1 (0.40) MEN1KMT2AKDM4EALDH1A1
SCHEMBL2462377 0.72
SCHEMBL2462378 0.72
(Z)-1,2-Diphenylethene SCHEMBL443 0.72 MAOB (0.73) CYP11B1CYP11B2MEN1KMT2AALDH1A1
(Z)-1,2-Diphenylethene SCHEMBL21847984 0.72 MAOB (0.73) CYP11B1CYP11B2MEN1KMT2AALDH1A1
(Z)-1,2-Diphenylethene SCHEMBL347707 0.72 MAOB (0.73) CYP11B1CYP11B2MEN1KMT2AALDH1A1
(Z)-1,2-Diphenylethene SCHEMBL22712863 0.72 MAOB (0.73) CYP11B1CYP11B2MEN1KMT2AALDH1A1
(Z)-1,2-Diphenylethene SCHEMBL9134305 0.72 MAOB (0.73) CYP11B1CYP11B2MEN1KMT2AALDH1A1
(Z)-1,2-Diphenylethene SCHEMBL9488270 0.72 MAOB (0.73) CYP11B1CYP11B2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016312-B2 Animal models, screening methods, and treatment methods for intraocular diseases or disorders Smilebiotek Zhuhai Limited (CN) 2024-06-25 US disclosed
US-12016312-B2 Animal models, screening methods, and treatment methods for intraocular diseases or disorders Smilebiotek Zhuhai Limited (CN) 2024-06-25 US disclosed
US-20220015338-A1 ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS Smilebiotek Zhuhai Limited (CN) 2022-01-20 US disclosed
US-20220016146-A1 METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION Smilebiotek Zhuhai Limited (CN) 2022-01-20 US disclosed
WO-2020113759-A1 METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION ZHUHAI QIWEI BIO-TECHNOLOGY LTD. (CN) 2020-06-11 WO disclosed
WO-2020113373-A1 METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION ZHUHAI QIWEI BIO-TECHNOLOGY LTD. (CN) 2020-06-11 WO disclosed
WO-2020098630-A1 ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS ZHUHAI QIWEI BIO-TECHNOLOGY LTD. (CN) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220016146-A1 METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION AGER, CASP3, PDE6D CYP11B1 1208/4885CYP11B2 1107/4885MEN1 2125/4885
US-12016312-B2 Animal models, screening methods, and treatment methods for intraocular diseases or disorders MB, MYOC, PDE6A CYP11B1 2284/4885CYP11B2 1925/4885MEN1 1097/4885
US-20220015338-A1 ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS MB, MYOC, PDE6A CYP11B1 2284/4885CYP11B2 1925/4885MEN1 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.